Revenue Breakdown
Composition ()
No data
Revenue Streams
Agenus Inc (AGEN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Non-cash royalty revenue, accounting for 96.4% of total sales, equivalent to $29.15M. Another important revenue stream is Clinical product revenue. Understanding this composition is critical for investors evaluating how AGEN navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Agenus Inc maintains a gross margin of 97.88%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -16.08%, while the net margin is 211.38%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively AGEN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, AGEN competes directly with industry leaders such as EQ and SAVA. With a market capitalization of $120.71M, it holds a leading position in the sector. When comparing efficiency, AGEN's gross margin of 97.88% stands against EQ's N/A and SAVA's N/A. Such benchmarking helps identify whether Agenus Inc is trading at a premium or discount relative to its financial performance.
